Expiration date: 01/2025

Composition and form of release:

1 ml of suspension for injection contains triamcinolone acetonide 40 mg and benzyl alcohol 9, 9 mg in an isotonic solution of sodium chloride in ampoules of 1 ml, in a box of 5 PCs.

Pharmacological action:

It induces the formation of lipocortins, inhibits the release of inflammatory mediators by eosinophils, and reduces the number of mast cells that produce hyaluronic acid. Impact capillary permeability, stabilizes cell, including lizosomaiona membranes and membrane. Inhibits the release of cytokines (interleukin 1, 2, gamma interferon) from lymphocytes and macrophages. Increases gluconeogenesis, reduces glucose utilization by tissues, and activates catabolic processes.

Indications:

Hay fever, bronchial asthma, chronic spastic bronchitis, pemphigoid, psoriasis, dermatitis (herpetic, atopic, exfoliative, contact non-microbial etiology, eczema). Intra-articular: chronic inflammatory joint diseases, exudative arthritis, gout, false gout, arthrosis, joint dropsy, shoulder joint block, chronic inflammation of the inner layer of the joint capsule injections under the affected area: isolated psoriatic plaques, flat nodular lesions, hair loss in the form of a circle, chronic lupus erythematosus, keloids.

Contraindications:

For systemic use — hypersensitivity, gastric and duodenal ulcers, bone atrophy, mental diseases (including a history), viral diseases (herpetic pemphigus, shingles), chickenpox, amoebic and fungal infections, childhood polio (except bulbar-encephalitis), glaucoma, age — from 12 to 16 years (I/m introduction). For topical use — chickenpox, conditions after immunization, skin lesions of a tuberculous or syphilitic nature, fungal diseases, skin lesions of a bacterial nature, inflammation of the skin around the mouth.

Use during pregnancy and lactation:

Not recommended.

Side effect:

In case of subcutaneous injection — reversible tissue atrophy in case of intra — articular injections- necrosis of bone tissue, feeling of heat. When used locally — thinning of the skin, acne, blisters, increased hair growth, changes in pigmentation. With systemic — moon face, Cushing's syndrome, adrenal atrophy, muscle weakness, bone and muscle atrophy, diabetes, menstruation disorders, impotence, increased hair growth, bleeding from the skin and mucous membranes, acne, potassium excretion, vasculitis, withdrawal syndrome, ulcerogenic effect, immune suppression, headaches, increased sweating, glaucoma, thrombosis.

Dosage and administration:

In/m, adults for systemic treatment — 1 ml (40 mg) slowly, deeply, intra-annually, up to 80 mg (repeated administration after 4 weeks). For intra — focal use (bursitis) in adults and children over 12 years of age-from 10 to 40 mg. The interval between injections is at least 2 weeks. When injected under the area of skin lesions, 1 ml is diluted with a local anesthetic and 1 mg of the drug is administered per 1 cm2 (no more than 30 mg per day in adults and 10 mg in children). Repeated injection — after 2 weeks.

Precautionary measures:

Care should be taken for stomach and duodenal ulcers (in the anamnesis), diverticulitis, fresh intestinal anastomoses, a tendency to thrombosis, embolism, carcinomas with a tendency to metastasis, acute glomerulonephritis, chronic nephritis. If there is an infection, do not enter intra-articular and p/K.